Background: The Autonomous Technologies LADARVision excimer laser system utilizes an eye tracking mechanism and a small spot for photorefractive keratectomy.
Methods: One hundred and two eyes of 102 patients were treated for -1.50 to -6.25 D of spherical myopia at the spectacle plane using a 6-mm diameter ablation zone. One year follow-up was available for 93 eyes (91%).
Results: Uncorrected visual acuity for eyes treated for distance vision was 20/40 or better in 99% (n = 90), and 20/20 or better in 70% (n = 64) of eyes at 12 months. Spectacle-corrected visual acuity was 20/25 or better in all 92 eyes reported; no eye lost more than 2 lines of spectacle-corrected visual acuity, and only 1 eye (1.0%) experienced a loss of 2 lines (20/12.5 to 20/20) at 1 year. The refractive result was within +/- 0.50 D of the desired correction in 75% (n = 70), and within +/- 1.00 D in 93% (n = 86) of eyes at 12 months. Refractive stability was achieved between 3 and 6 months. Corneal haze was graded as trace or less in 100% of the 93 eyes. No significant reductions were noted in contrast sensitivity or endothelial cell density.
Conclusions: Patients treated with the Autonomous Technologies LADARVision excimer laser system for -1.50 to -6.25 D of spherical myopia with 1 year follow-up had uncorrected visual acuity of 20/20 or better in 70%, no significant loss of spectacle-corrected visual acuity, no reduction of endothelial cell density or contrast sensitivity, and low levels of corneal haze.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3928/1081-597X-19990301-10 | DOI Listing |
Eye Contact Lens
January 2025
Department of Ophthalmology (B.S., A.S., S.B., J.K.), Emory University School of Medicine, Atlanta, GA; and Emory University School of Medicine (S.C.), Atlanta, GA.
Purpose: Symptom management in Ocular Cicatricial Pemphigoid (OCP) is challenging because of the progressive factors of dry eye, scarring, trichiasis, and vision impairment. We set out to evaluate the benefits and therapeutic effects of scleral contact lenses in the management of OCP.
Methods: A retrospective review was performed over a database of 20 patients (36 eyes) fitted with scleral lenses (SL) at the Department of Ophthalmology, Emory University from May 2018 to April 2021.
Vopr Kurortol Fizioter Lech Fiz Kult
January 2025
Russian University of Medicine of the Ministry of Health of the Russian Federation, Moscow, Russia.
Objective: To evaluate the effectiveness of a treatment complex including magnetophoresis with the drug «Argensept» and tear therapy in patients with mild to moderate dry eye syndrome.
Material And Methods: The study was conducted on 50 people (100 eyes) diagnosed with mild to moderate dry eye syndrome (H04.1 according to ICD-10).
Cureus
December 2024
Ophthalmology, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, TUR.
Purpose This study evaluated the efficacy of oral melatonin therapy for visual acuity and retinal and choroidal structures in patients with chronic central serous chorioretinopathy (CSCR). Methods Fourteen patients with CSCR were included; eight received oral melatonin (3 mg nightly), and six formed the control group. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and choroidal vascularity index (CVI) were assessed at baseline and after one month.
View Article and Find Full Text PDFCureus
December 2024
Department of Ophthalmology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.
Optic nerve disorders significantly contribute to visual impairment with irreversible visual deficits. Current treatments have limited efficacy in resolving chronic visual deficits, necessitating novel therapeutic strategies. Neurorehabilitation techniques, including repetitive transorbital alternating current stimulation (rtACS), have emerged as promising approaches to restore lost visual function through the ability to modulate brain activity.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!